These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 2288718)

  • 1. Potential therapeutic applications of PHA-L4, the mitogenic isolectin of phytohemagglutinin.
    Wimer BM
    Mol Biother; 1990 Dec; 2(4):196-200. PubMed ID: 2288718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic activities of PHA-L4, the mitogenic isolectin of phytohemagglutinin.
    Wimer BM
    Mol Biother; 1990 Jun; 2(2):74-90. PubMed ID: 2194501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characteristics of PHA-L4, the mitogenic isolectin of phytohemagglutinin, as an ideal biologic response modifier.
    Wimer BM
    Mol Biother; 1990 Mar; 2(1):4-17. PubMed ID: 2185793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ideal biological response modifier.
    Wimer BM
    Mol Biother; 1989; 1(6):311-7. PubMed ID: 2692630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PHA for aplastic anemias: the alpha but not the omega of mitogen therapies.
    Wimer BM
    Cancer Biother Radiopharm; 1998 Apr; 13(2):109-20. PubMed ID: 10850347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitogen immunotherapy for HIV infections exemplified by phytohemagglutinin and pokeweed mitogen.
    Wimer BM; Mann PL
    Cancer Biother Radiopharm; 2000 Dec; 15(6):629-44. PubMed ID: 11190495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic immunostimulating effects of plant mitogens exemplified by the L4 isolectin of PHA.
    Wimer BM
    Cancer Biother Radiopharm; 1997 Jun; 12(3):195-212. PubMed ID: 10851466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiproliferative response of human leukemic cells: lectin induced inhibition of DNA synthesis and cellular metabolism.
    Borrebaeck CA; Schön A
    Cancer Res; 1987 Aug; 47(16):4345-50. PubMed ID: 3607766
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Affinity of phytohemagglutinin (PHA) isolectins for serum proteins and regulation of the lectin-induced lymphocyte transformation.
    Glad C; Borrebaeck CA
    J Immunol; 1984 Oct; 133(4):2126-32. PubMed ID: 6236263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic response modifiers in cancer therapy: a review.
    Quesada JR
    Tex Med; 1989 Nov; 85(11):42-7. PubMed ID: 2686076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protease inhibitors as immunomodulatory drugs for HIV infection.
    Deeks SG
    Clin Pharmacol Ther; 2007 Sep; 82(3):248-50. PubMed ID: 17700590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges.
    Shen RN; Lu L; Kaiser HE; Broxmeyer HE
    In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retroviruses and other latent viruses: the deadliest of pathogens are not necessarily the best candidates for bioterrorism.
    Salgado CD; Kilby JM
    J S C Med Assoc; 2009 Jun; 105(3):104-6. PubMed ID: 19639767
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-induced immunodeficiency. Relatively preserved phytohemagglutinin as opposed to decreased pokeweed mitogen responses may be due to possibly preserved responses via CD2/phytohemagglutinin pathway.
    Hofmann B; Jakobsen KD; Odum N; Dickmeiss E; Platz P; Ryder LP; Pedersen C; Mathiesen L; Bygbjerg IB; Faber V
    J Immunol; 1989 Mar; 142(6):1874-80. PubMed ID: 2564029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic therapy in patients receiving salvage treatment.
    Bukowski RM
    Semin Oncol; 1994 Aug; 21(4 Suppl 7):96-9. PubMed ID: 8091247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationales for combining chemotherapy and biotherapy in the treatment of cancer.
    Dillman RO
    Mol Biother; 1990 Dec; 2(4):201-7. PubMed ID: 2288719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis.
    Mascarell L; Fayolle C; Bauche C; Ladant D; Leclerc C
    J Virol; 2005 Aug; 79(15):9872-84. PubMed ID: 16014948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Searching for clues to effective use of biologic response modifiers.
    Kovach JS
    J Natl Cancer Inst; 1991 Jan; 83(1):2-3. PubMed ID: 1878016
    [No Abstract]   [Full Text] [Related]  

  • 20. Measles as a potential oncolytic virus.
    Fielding AK
    Rev Med Virol; 2005; 15(2):135-42. PubMed ID: 15546127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.